

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

28 May 2026

### Study of the effects of Rosuvastatin in the treatment of patients with acute deep vein thrombosis(DVT) of lower extremities

#### Protocol summary

##### Study aim

The effect of using rosuvastatin in the treatment of patients with deep vein thrombosis

##### Design

A non-randomized, parallel group, phase 3 trial with a control group and blinded outcome assessment. The sample size is 50 patients in each group.

##### Settings and conduct

This clinical trial study will conduct on DVT patients in Shohada Tajrish, Shahid Modares, and Shahid Labafinejad hospitals. After confirmation of DVT diagnosis, explaining the research goals and duration, and obtaining written consent patients will be enrolled in the study. The evaluators won't inform about the results of the study and group classification. In this study, patients will be treated with Warfarin, Warfarin + Rosuvastatin, rivaroxaban, and Rivaroxaban + Rosuvastatin, respectively. The duration of the study will be 3 months. After the completion of the study, the serum CRP, D-dimer level, the extent of the difference in the size of the lower extremity, as well as the prevalence of PPS will be measured.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients older than 18 years of age  
Exclusion criteria: Patients with ESRD and patients with CRF who had a GFR below 1.73 mL/min/1.73 m<sup>2</sup>. Patients who need any invasive intervention for treatment of DVT  
Patients with active malignancy. Any medical conditions which can interfere with the serum level of CRP and D-dimer. Previous use of statins. Presence of any statin contraindications Bilateral lower limb DVT

##### Intervention groups

1-Warfarin 2-Warfarin + Rosuvastatin 3- Rivaroxaban 4- Rivaroxaban + Rosuvastatin

##### Main outcome variables

Primary outcome: Prevalence of Post thrombotic Phlebitis Syndrome  
Secondary Outcome: Serum CRP and D-dimer levels before and after treatment

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20150621022852N4**

Registration date: **2019-02-27, 1397/12/08**

Registration timing: **retrospective**

Last update: **2019-02-27, 1397/12/08**

Update count: **0**

##### Registration date

2019-02-27, 1397/12/08

##### Registrant information

##### Name

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 44429613

##### Email address

dr.s.asaadi@sbmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2017-05-22, 1396/03/01

##### Expected recruitment end date

2018-05-22, 1397/03/01

##### Actual recruitment start date

2017-09-25, 1396/07/03

##### Actual recruitment end date

2018-09-20, 1397/06/29

##### Trial completion date

2019-01-21, 1397/11/01

##### Scientific title

Study of the effects of Rosuvastatin in the treatment of

patients with acute deep vein thrombosis(DVT) of lower extremities

### Public title

Evaluation of the effects of Rosuvastatin in the treatment of patients with deep vein thrombosis(DVT)

### Purpose

Prevention

### Inclusion/Exclusion criteria

#### Inclusion criteria:

All patients with unilateral Deep Vein thrombosis of the lower extremities.

#### Exclusion criteria:

Patients with ESRD who underwent regular dialysis and patients with CRF who had GFR below 1.73 mL / min. Patients need any invasive intervention in the treatment of DVT. The patient with any illness, including infection and sepsis, which can interfere with the level of inflammatory factors and D-dimer. Patients with history of active malignancy. Bilateral lower limb DVT

### Age

From **18 years** old to **80 years** old

### Gender

Both

### Phase

3

### Groups that have been masked

- Outcome assessor

### Sample size

Target sample size: **50**

Actual sample size reached: **50**

### Randomization (investigator's opinion)

Not randomized

### Randomization description

### Blinding (investigator's opinion)

Single blinded

### Blinding description

This blindness study was conducted on clinical outcomes evaluators. Clinical outcomes evaluated only patients at the end of the study and did not play any role in initiating and tracking patients.

### Placebo

Not used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Shahid Beheshti University of Medical Sciences

##### Street address

7th Floor, Bldg No.2 SBUM, Arabi Ave, Daneshjoo

Blvd, Velenjak,

### City

Teharn

### Province

Tehran

### Postal code

19839-63113

### Approval date

2017-12-19, 1396/09/28

### Ethics committee reference number

IR.SBMU.REC.1396.651

## Health conditions studied

### 1

#### Description of health condition studied

Deep Vein Thrombosis

#### ICD-10 code

I80.2

#### ICD-10 code description

Phlebitis and thrombophlebitis of other deep vessels of lower extremities

## Primary outcomes

### 1

#### Description

The incidence of post thrombotic phlebitis syndrome

#### Timepoint

After three months from the start of the study

#### Method of measurement

Based on clinical criteria according to Brandjes questionnaire

## Secondary outcomes

### 1

#### Description

Serum levels of C-reactive protein, D-Dimer, as well as lower limb size

#### Timepoint

At the end of the third month of study

#### Method of measurement

Using serum samples to measure serum CRP and D-dimer levels, as well as instrumentation for measuring lower limb size.

## Intervention groups

### 1

#### Description

Control group: Patients are being treated with warfarin. Drug daily intake of 5 to 10 mg with the goal of maintaining an INR level of 2-3.

#### Category

Prevention

## 2

### **Description**

Intervention group: Rivaroxaban group. The dose was 15 mg daily BD daily and then 20 mg daily for the first 3 weeks.

### **Category**

Prevention

## 3

### **Description**

Intervention group: Warfarin + Resostatin. Warfarin usage similar to the control group plus 20 mg of rosuvastatin daily

### **Category**

Prevention

## 4

### **Description**

Intervention group: Rivaroxaban + Rosuvastatin. The rivaroxaban dose was 15 mg daily BD daily, followed by 20 mg daily, plus daily 20 mg of rosuvastatin.

### **Category**

Prevention

## **Recruitment centers**

## 1

### **Recruitment center**

#### **Name of recruitment center**

Shohada-e-tajrish hospital

#### **Full name of responsible person**

Dr. Mehdi Pishgahi

#### **Street address**

Tajrish sq.Valiasr st

#### **City**

tehran

#### **Province**

Tehran

#### **Postal code**

1989934148

#### **Phone**

+98 21 25719

#### **Email**

pr\_shohada@sbmu.ac.ir

## 2

### **Recruitment center**

#### **Name of recruitment center**

Shahid Modares Hospital

#### **Full name of responsible person**

Dr. Mahdi Pishgahi

#### **Street address**

Saadat Abad,Kaj Sq, Shahid Modares Hospital

#### **City**

Tehran

#### **Province**

Tehran

#### **Postal code**

1998734383

#### **Phone**

+98 21 2207 4087

#### **Email**

modarres@sbmu.ac.ir

## 3

### **Recruitment center**

#### **Name of recruitment center**

Shahid labafinejad Hospital

#### **Full name of responsible person**

Dr. Mehdi Pishgahi

#### **Street address**

Pasdaran st, 9 th Boustan

#### **City**

Tehran

#### **Province**

Tehran

#### **Postal code**

19839-63113

#### **Phone**

+98 21 23601

#### **Email**

lamc@sbmu.ac.ir

## **Sponsors / Funding sources**

## 1

### **Sponsor**

#### **Name of organization / entity**

Shahid Beheshti University of Medical Sciences

#### **Full name of responsible person**

Dr. Afshin Zarghi

#### **Street address**

7th Floor, Bldg No.2 SBUMS, Arabi Ave, Daneshjoo Blvd, Velenjak

#### **City**

Tehran

#### **Province**

Tehran

#### **Postal code**

19839-63113

#### **Phone**

+98 21 2243 9770

#### **Email**

info@sbmu.ac.ir

#### **Grant name**

#### **Grant code / Reference number**

#### **Is the source of funding the same sponsor organization/entity?**

Yes

#### **Title of funding source**

Shahid Beheshti University of Medical Sciences

#### **Proportion provided by this source**

100

#### **Public or private sector**

Public

#### **Domestic or foreign origin**

Domestic

#### **Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Dr. Mehdi Pishgahi

**Position**

Assistance Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Cardiology

**Street address**

Shohada Tajrsih Hosptal,Tajrish sq

**City**

Tehran

**Province**

Tehran

**Postal code**

1989934148

**Phone**

+98 21 25719

**Email**

M.pishgahi@gmail.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Dr. Mehdi Pishgahi

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Cardiology

**Street address**

Shohada Tajrish Hospital,Tajrish sq

**City**

Tehran

**Province**

Tehran

**Postal code**

1989934148

**Phone**

+98 21 25719

**Email**

M.pishgahi@gmail.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Dr. Sina Asaadi

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

General Surgery

**Street address**

7th Floor, Bldg No.2 SBUMS, Arabi Ave, Daneshjoo Blvd, Velenjak

**City**

Tehran

**Province**

Tehran

**Postal code**

19839-63113

**Phone**

+98 21 2243 9770

**Fax**

**Email**

dr.s.asaadi@sbm.ac.ir

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available

**Title and more details about the data/document**

All information about the outcome of the study, will be available after concealment.

**When the data will become available and for how long**

One year after the publication of the study results

**To whom data/document is available**

Researchers and university students of related fields can access the data after passing the administrative process.

**Under which criteria data/document could be used**

A study observer appointed by the ethics committee of Shahid Beheshti University of Medical Sciences can request to receive data after being unidentifiable in order to control the ethical aspects of the study.

**From where data/document is obtainable**

Head of the Center for Development of Clinical Research - Management of Shohada Tajrish Hospital

**What processes are involved for a request to access data/document**

To receive data, please contact the Shohada Tajrish Hospital Clinical Development Center. After obtaining permission from the Head of the Research Center and

then the Shohada Tajrish Hospital, access to patient

information and study will be provided.  
**Comments**